Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
Study Identifier:
ENB-003-08
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: asfotase alfa
Date
Apr 2009 - Aug 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 24 Weeks - 42 Months
Requirements Information
Sex
Female & Male
Age
24 Weeks - 42 Months
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: asfotase alfa
Date
Apr 2009 - Aug 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 24 Weeks - 42 Months years
Requirements Information
Protocol Summary
This clinical trial studied the long term safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP who completed study ENB-002-08 (NCT00744042).
Partial funding for this study was provided by the Office of Orphan Product Development (OOPD).
Trial Locations
Location
Status
Location
Alfred I. DuPont Hospital for Children
Wilmington, Delaware, United States, 19803
Status
N/A
Location
St. John's Medical Research Institute
Springfield, Missouri, United States, 65807
Status
N/A
Location
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Status
N/A
Location
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Status
N/A
Location
St. Vincent Hospital
Green Bay, Wisconsin, United States, 54301
Status
N/A
Location
Tawam Hospital
Al Ain, Abu-Dhabi, United Arab Emirates
Status
N/A